Cargando…

Clinical significance of mucinous component in colorectal adenocarcinoma: a propensity score-matched study

BACKGROUND: This study aims to investigate the clinical significance and prognostic value of mucinous component (MC) in colorectal adenocarcinoma (AC). METHODS: Patients with colorectal AC and AC with MC (ACMC) (1–100%) underwent surgical resection between January 2007 and February 2018 were retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Chuanwang, Yang, Hui, Chen, Lili, Liu, Ran, Shang, Wei, Yuan, Wenguang, Yang, Fei, Sun, Qing, Xia, Lijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638428/
https://www.ncbi.nlm.nih.gov/pubmed/34852768
http://dx.doi.org/10.1186/s12885-021-09031-9
_version_ 1784608943717220352
author Yan, Chuanwang
Yang, Hui
Chen, Lili
Liu, Ran
Shang, Wei
Yuan, Wenguang
Yang, Fei
Sun, Qing
Xia, Lijian
author_facet Yan, Chuanwang
Yang, Hui
Chen, Lili
Liu, Ran
Shang, Wei
Yuan, Wenguang
Yang, Fei
Sun, Qing
Xia, Lijian
author_sort Yan, Chuanwang
collection PubMed
description BACKGROUND: This study aims to investigate the clinical significance and prognostic value of mucinous component (MC) in colorectal adenocarcinoma (AC). METHODS: Patients with colorectal AC and AC with MC (ACMC) (1–100%) underwent surgical resection between January 2007 and February 2018 were retrospectively reviewed. Propensity score matching (PSM) was performed according to a 1:1 ratio. Receiver-operating characteristic (ROC) curve was used to identify the optimal cut-off value of MC ratio for prognostic prediction. The clinicopathological features and 3-year overall survival (OS) of AC patients, mucinous adenocarcinoma (MAC) (MC > 50%) patients, and ACMC (1–50%) patients were compared before and after matching. Multivariable analysis was used for analyzing independent risk factors related to prognosis. RESULTS: A total of 532 patients were enrolled in this study. Patients with AC, MAC, and ACMC (1–50%) exhibited different clinicopathological features. However, their 3-year OS rates were similar (82.00% vs. 74.11% vs. 81.48%, P = 0.38). After matching, ROC curve determined 70% as the optimal cut-off value. And patients with ACMC > 70% had a much poorer 3-year OS compared with ACMC (1–70%) patients and AC patients (47.37% vs. 86.15% vs. 79.76%, P < 0.001). In addition, ACMC > 70% was revealed as a risk factor for poor survival in univariate analysis (HR = 1.643, 95%CI = 1.025–2.635, P = 0.039), though not an independent risk factor in multivariable analysis (HR = 1.550, 95%CI = 0.958–2.507, P = 0.074). CONCLUSIONS: MAC is usually diagnosed at an advanced stage. MAC has a similar survival with AC and ACMC (1–50%) patients before and after matching. Patients with ACMC > 70% exhibited a much poorer OS, and should be given more clinical attention.
format Online
Article
Text
id pubmed-8638428
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86384282021-12-03 Clinical significance of mucinous component in colorectal adenocarcinoma: a propensity score-matched study Yan, Chuanwang Yang, Hui Chen, Lili Liu, Ran Shang, Wei Yuan, Wenguang Yang, Fei Sun, Qing Xia, Lijian BMC Cancer Research BACKGROUND: This study aims to investigate the clinical significance and prognostic value of mucinous component (MC) in colorectal adenocarcinoma (AC). METHODS: Patients with colorectal AC and AC with MC (ACMC) (1–100%) underwent surgical resection between January 2007 and February 2018 were retrospectively reviewed. Propensity score matching (PSM) was performed according to a 1:1 ratio. Receiver-operating characteristic (ROC) curve was used to identify the optimal cut-off value of MC ratio for prognostic prediction. The clinicopathological features and 3-year overall survival (OS) of AC patients, mucinous adenocarcinoma (MAC) (MC > 50%) patients, and ACMC (1–50%) patients were compared before and after matching. Multivariable analysis was used for analyzing independent risk factors related to prognosis. RESULTS: A total of 532 patients were enrolled in this study. Patients with AC, MAC, and ACMC (1–50%) exhibited different clinicopathological features. However, their 3-year OS rates were similar (82.00% vs. 74.11% vs. 81.48%, P = 0.38). After matching, ROC curve determined 70% as the optimal cut-off value. And patients with ACMC > 70% had a much poorer 3-year OS compared with ACMC (1–70%) patients and AC patients (47.37% vs. 86.15% vs. 79.76%, P < 0.001). In addition, ACMC > 70% was revealed as a risk factor for poor survival in univariate analysis (HR = 1.643, 95%CI = 1.025–2.635, P = 0.039), though not an independent risk factor in multivariable analysis (HR = 1.550, 95%CI = 0.958–2.507, P = 0.074). CONCLUSIONS: MAC is usually diagnosed at an advanced stage. MAC has a similar survival with AC and ACMC (1–50%) patients before and after matching. Patients with ACMC > 70% exhibited a much poorer OS, and should be given more clinical attention. BioMed Central 2021-12-01 /pmc/articles/PMC8638428/ /pubmed/34852768 http://dx.doi.org/10.1186/s12885-021-09031-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yan, Chuanwang
Yang, Hui
Chen, Lili
Liu, Ran
Shang, Wei
Yuan, Wenguang
Yang, Fei
Sun, Qing
Xia, Lijian
Clinical significance of mucinous component in colorectal adenocarcinoma: a propensity score-matched study
title Clinical significance of mucinous component in colorectal adenocarcinoma: a propensity score-matched study
title_full Clinical significance of mucinous component in colorectal adenocarcinoma: a propensity score-matched study
title_fullStr Clinical significance of mucinous component in colorectal adenocarcinoma: a propensity score-matched study
title_full_unstemmed Clinical significance of mucinous component in colorectal adenocarcinoma: a propensity score-matched study
title_short Clinical significance of mucinous component in colorectal adenocarcinoma: a propensity score-matched study
title_sort clinical significance of mucinous component in colorectal adenocarcinoma: a propensity score-matched study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638428/
https://www.ncbi.nlm.nih.gov/pubmed/34852768
http://dx.doi.org/10.1186/s12885-021-09031-9
work_keys_str_mv AT yanchuanwang clinicalsignificanceofmucinouscomponentincolorectaladenocarcinomaapropensityscorematchedstudy
AT yanghui clinicalsignificanceofmucinouscomponentincolorectaladenocarcinomaapropensityscorematchedstudy
AT chenlili clinicalsignificanceofmucinouscomponentincolorectaladenocarcinomaapropensityscorematchedstudy
AT liuran clinicalsignificanceofmucinouscomponentincolorectaladenocarcinomaapropensityscorematchedstudy
AT shangwei clinicalsignificanceofmucinouscomponentincolorectaladenocarcinomaapropensityscorematchedstudy
AT yuanwenguang clinicalsignificanceofmucinouscomponentincolorectaladenocarcinomaapropensityscorematchedstudy
AT yangfei clinicalsignificanceofmucinouscomponentincolorectaladenocarcinomaapropensityscorematchedstudy
AT sunqing clinicalsignificanceofmucinouscomponentincolorectaladenocarcinomaapropensityscorematchedstudy
AT xialijian clinicalsignificanceofmucinouscomponentincolorectaladenocarcinomaapropensityscorematchedstudy